Hims and Hers to Buy Peptide Facility

Hims & Hers Health, Inc. (NYSE:HIMS) shares stumbled Friday afternoon. The company, the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s long-term ability to deliver personalized medications. The company has acquired a U.S.-based peptide facility based in California. The acquisition will enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment options.“The future of healthcare must be centered on the customer, which is why our operational structure is built to scale personalized care to more individuals at the highest standard of quality and safety, and with a focus on long-term consistency and availability,” said Melissa Baird, COO of Hims & Hers. “We're building our supply chain to enable more Americans to access care, including personalized treatments designed around their needs. This acquisition is a reflection of our commitment to those goals and our ongoing investment in the customer from start to finish.”Following the company’s past acquisitions of 503A and 503B facilities, this additional facility deepens the company’s commitment to maintaining operations in the United States for better insight into cost, availability and quality, more fully verticalizing the efficiency and durability of the supply chain, and furthering the company’s focus on quality and safety for every customer on the platform. HIMS shares collapsed $12.41, or 18.7%, to $54.00.